FDA Warning Letter Highlights AI Oversight Risks in Clinical Trials
FDA’s warning letter signals a shift: AI use without oversight is a compliance risk. What clinical trial teams must understand to stay inspection-ready.
Risk-Based Quality Management in Medical Devices: ISO 14155 vs ICH E6(R3)
Medical device investigations are now assessed like RBQM trials. Learn how ISO 14155 and ICH E6(R3) align and download the practical translation guide.
From spreadsheets to Digital RACT | ICH E6(R3) compliance
Learn why spreadsheet-based RACT falls short of ICH E6(R3) and how Digital RACT in the MyRBQM Portal delivers traceable, inspection-ready risk governance.
From EMA Findings to ICH E6(R3): QbD and RBQM in Practice
How EMA inspection findings translate into ICH E6(R3) expectations, and why Quality by Design and RBQM must operate together in clinical trials.
Risk-based quality management in 2026
Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials.
FDA AI Guidance 2025 Interactive Visualizer
Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios.
ICH E6(R3) Interactive Visualizer: GCP Explained Visually
Explore the evolution of Good Clinical Practice with an interactive ICH E6(R3) visualizer showing ethics, risk-based oversight, and modern GCP design.
EMA Clinical Trials Map Visualizer Explained
Explore how the EMA Clinical Trials Map visualizes trial activity across Europe to support recruitment planning and site strategy decisions.
MyRBQM® Portal Onboarding Plan
Download the MyRBQM® Portal Onboarding Plan — a realistic 3–6-month roll-out blueprint covering pilots, integrations, governance, validation, and hypercare. Adaptable to in-house, hybrid, and outsourced delivery models.
Phase III Oncology: Targeted Risk-Based QA Case Study
How ADAMAS used AI-augmented RBQM analytics to strengthen oversight, focus QA effort, and improve inspection readiness in a global Phase III oncology study.
